Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.81 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 10/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.77 |
| ▸ | NPC1 | O15118 | 8/20 | 0.77 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | HTT | P42858 | 4/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.77 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.77 |
| ▸ | PDE4A | P27815 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.77 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.77 |
| ▸ | CBS | P35520 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 7/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | RAB9A | P51151 | 7/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683478 | 0.90 | EPHX1 (1.00) | EPHX1EPHX2MEN1KMT2ANPC1 | |
| SCHEMBL30640703 | 0.90 | EPHX1 (1.00) | EPHX1EPHX2MEN1KMT2ANPC1 | |
| Triclocarban SCHEMBL8076465 | 0.87 | NPC1 (0.79) | EPHX1EPHX2MEN1KMT2ANPC1 | |
| Triclocarban SCHEMBL27313500 | 0.87 | MEN1 (1.00) | EPHX1EPHX2MEN1KMT2ANPC1 | |
| Triclocarban SCHEMBL68658 | 0.87 | MEN1 (1.00) | EPHX1EPHX2MEN1KMT2ANPC1 | |
| Triclocarban SCHEMBL30479188 | 0.87 | MEN1 (1.00) | EPHX1EPHX2MEN1KMT2ANPC1 | |
| Triclocarban SCHEMBL4978963 | 0.87 | MEN1 (1.00) | EPHX1EPHX2MEN1KMT2ANPC1 | |
| SCHEMBL4358566 | 0.86 | MEN1 (0.69) | EPHX1EPHX2MEN1KMT2ANPC1 | |
| SCHEMBL457521 | 0.86 | MEN1 (0.79) | EPHX1EPHX2MEN1KMT2ANPC1 | |
| Triclocarban SCHEMBL10888069 | 0.85 | MEN1 (0.96) | EPHX1EPHX2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001007431-A2 | BENZOTHIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-02-01 | — | — | WO | claimed |
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | DUKE UNIVERSITY (US) | 2024-09-24 | — | — | US | disclosed |
| US-20220106265-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3894392-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Duke University (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-111902088-A | Imaging table and method for manufacturing the same, imaging table for molybdenum target inspection device and method for manufacturing the same, and molybdenum target inspection device | 东丽株式会社 | 2020-11-06 | — | — | CN | disclosed |
| WO-2020123675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2001007431-A2 | BENZOTHIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | EPHX1 3300/4885EPHX2 3586/4885MEN1 4220/4885 |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | HSF1, HSP90AB1, HSP90AA1 | EPHX1 3300/4885EPHX2 3586/4885MEN1 4220/4885 |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | EPHX1 3300/4885EPHX2 3586/4885MEN1 4220/4885 |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | TP53, NUP205, ANXA5 | EPHX1 2723/4885EPHX2 3481/4885MEN1 2133/4885 |
| US-20220106265-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | EPHX1 3300/4885EPHX2 3586/4885MEN1 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.